Novo Nordisk: collaboration deal with Valo Health
(CercleFinance.com) - Novo Nordisk announces that it has entered into an agreement with Valo Health to discover and develop new treatments for cardiometabolic diseases based on Valo's vast human dataset and artificial intelligence (AI)-powered computing.
The collaboration will use Valo's Opal informatics platform and a real-world patient dataset to enable the discovery and development of new drug programs.
The Danish pharmaceutical company is licensing three preclinical drug discovery programs in cardiovascular disease discovered and developed by Valo using its Opal computing platform.
Valo will receive an upfront payment and a potential short-term milestone payment, totaling $60m, and will be eligible for milestone payments for up to 11 management programs, for $2.7bn, plus R&D funding and potential royalties.
Copyright (c) 2023 CercleFinance.com. All rights reserved.